Table 1.
Baseline characteristics.
| n (%) or mean (sd) | |
|---|---|
| Gender | |
| Male | 57 (29.5) |
| Female | 136 (70.5) |
| Age, years (mean (sd)) | 51.3 (13.8) |
| <40 | 44 (22.8) |
| 40–65 | 115 (59.6) |
| >65 | 34 (17.6) |
| School education 1 | |
| Low | 16 (8.6) |
| Middle | 54 (28.9) |
| High | 113 (60.4) |
| Not specified | 4 (2.1) |
| City resident size | |
| <5,000 | 77 (41.0) |
| 5,000–20,000 | 36 (19.1) |
| 20,000–100,000 | 24 (12.8) |
| >100,000 | 51 (27.1) |
| Household* | |
| Parenting | 47 (24.2) |
| Single parent | 2 (1.0) |
| Living alone | 38 (19.6) |
| Care of relatives | 22 (11.3) |
| Underlying disease* | |
| Rheumatological disease | 82 (42.3) |
| Inflammatory bowel disease | 39 (20.1) |
| Psoriasis | 27 (13.9) |
| Multiple sclerosis | 21 (10.8) |
| Transplant | 14 (7.2) |
| Other | 22 (11.3) |
| Comorbidities* | |
| Hypertension | 76 (39.2) |
| Heart failure | 2 (1.0) |
| Diabetes type 2 | 8 (4.1) |
| COPD | 2 (1.0) |
| Degree of impairment (%) 2 | |
| No impairment (0) | 71 (36.8) |
| Low impairment (20–49) | 39 (20.2) |
| Moderate impairment (50–74) | 63 (32.6) |
| Severe impairment (75–100) | 20 (10.4) |
| Therapy paused for COVID vaccination (yes) | 48 (24.7) |
| Immunosuppression medication* | |
| Prednisolone | 68 (35.1) |
| Methotrexate | 52 (26.8) |
| TNF inhibitor | 43 (22.2) |
| Azathioprine | 13 (6.7) |
| Tacrolimus & Everolimus | 12 (6.2) |
| Others | 51 (26.3) |
| Number of taken immunosuppressants | |
| 1 | 115 (59.3) |
| 2 | 60 (30.9) |
| 3 or more | 19 (9.8) |
| Vaccination type | |
| mRNA | 146 (77.7) |
| Vector-based | 14 (7.4) |
| Cross vaccinated3 | 28 (14.9) |
1based on German secondary school education, 2based on the German social law measuring physical, mental and social impairment *Multiple selection possible; COPD: chronic obstructive pulmonary disease 3consisting of one dose mRNA vaccination and one dose vector-based vaccination.